Literature DB >> 16795013

A global examination of allometric scaling for predicting human drug clearance and the prediction of large vertical allometry.

Huadong Tang1, Michael Mayersohn.   

Abstract

Allometrically scaled data sets (138 compounds) used for predicting human clearance were obtained from the literature. Our analyses of these data have led to four observations. (1) The current data do not provide strong evidence that systemic clearance (CL(s); n = 102) is more predictable than apparent oral clearance (CL(po); n = 24), but caution needs to be applied because of potential CL(po) prediction error caused by differences in bioavailability across species. (2) CL(s) of proteins (n = 10) can be more accurately predicted than that of non-protein chemicals (n = 102). (3) CL(s) is more predictable for compounds eliminated by renal or biliary excretion (n = 33) than by metabolism (n = 57). (4) CL(s) predictability for hepatically eliminated compounds followed the order: high CL (n = 11) > intermediate CL (n = 17) > low CL (n = 29). All examples of large vertical allometry (% error of prediction greater than 1000%) occurred only when predicting human CL(s) of drugs having very low CL(s). A qualitative analysis revealed the application of two potential rules for predicting the occurrence of large vertical allometry: (1) ratio of unbound fraction of drug in plasma (f(u)) between rats and humans greater than 5; (2) C logP greater than 2. Metabolic elimination could also serve as an additional indicator for expecting large vertical allometry. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16795013     DOI: 10.1002/jps.20481

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  21 in total

1.  A quantitative framework and strategies for management and evaluation of metabolic drug-drug interactions in oncology drug development: new molecular entities as object drugs.

Authors:  Karthik Venkatakrishnan; Michael D Pickard; Lisa L von Moltke
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

Review 2.  Applications of human pharmacokinetic prediction in first-in-human dose estimation.

Authors:  Peng Zou; Yanke Yu; Nan Zheng; Yongsheng Yang; Hayley J Paholak; Lawrence X Yu; Duxin Sun
Journal:  AAPS J       Date:  2012-03-10       Impact factor: 4.009

3.  Allometry of factor VIII and informed scaling of next-generation therapeutic proteins.

Authors:  Matthew P Kosloski; Dipak S Pisal; Donald E Mager; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2013-04-25       Impact factor: 3.534

4.  Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons.

Authors:  Leonid Kagan; Anson K Abraham; John M Harrold; Donald E Mager
Journal:  Pharm Res       Date:  2010-03-16       Impact factor: 4.200

5.  Clinical Micro-Dose Studies to Explore the Human Pharmacokinetics of Four Selective Inhibitors of Human Nav1.7 Voltage-Dependent Sodium Channels.

Authors:  Hannah M Jones; Richard P Butt; Rob W Webster; Ian Gurrell; Pawel Dzygiel; Neil Flanagan; Daniela Fraier; Tanya Hay; Laura Else Iavarone; Jacquelynn Luckwell; Hannah Pearce; Alex Phipps; Jill Segelbacher; Bill Speed; Kevin Beaumont
Journal:  Clin Pharmacokinet       Date:  2016-07       Impact factor: 6.447

6.  Physiologically-based modeling and interspecies prediction of paclitaxel pharmacokinetics.

Authors:  Xiaowei Zang; Leonid Kagan
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-04-18       Impact factor: 2.745

7.  Pharmacodynamic model of sodium-glucose transporter 2 (SGLT2) inhibition: implications for quantitative translational pharmacology.

Authors:  Tristan S Maurer; Avijit Ghosh; Nahor Haddish-Berhane; Aarti Sawant-Basak; Carine M Boustany-Kari; Li She; Michael T Leininger; Tong Zhu; Meera Tugnait; Xin Yang; Emi Kimoto; Vincent Mascitti; Ralph P Robinson
Journal:  AAPS J       Date:  2011-08-26       Impact factor: 4.009

8.  Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?

Authors:  Rong Deng; Suhasini Iyer; Frank-Peter Theil; Deborah L Mortensen; Paul J Fielder; Saileta Prabhu
Journal:  MAbs       Date:  2011-01-01       Impact factor: 5.857

9.  Predicting oral clearance in humans: how close can we get with allometry?

Authors:  Vikash K Sinha; Stefan S De Buck; Luca A Fenu; Johan W Smit; Marjoleen Nijsen; Ron A H J Gilissen; Achiel Van Peer; Karel Lavrijsen; Claire E Mackie
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 10.  Microdosing and drug development: past, present and future.

Authors:  Graham Lappin; Robert Noveck; Tal Burt
Journal:  Expert Opin Drug Metab Toxicol       Date:  2013-04-04       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.